Skip to main content
OBIO
NASDAQ Industrial Applications And Services

Orchestra BioMed to Receive Up to $21M from Vivasure Acquisition by Haemonetics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.98
Mkt Cap
$273.289M
52W Low
$2.2
52W High
$6.16
52W Position info
126% above low
Off High info
19% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

OBIO has more than doubled off its 52-week low of $2.2.

Summary

Orchestra BioMed Holdings, Inc. announced it will receive up to $21 million in proceeds from the acquisition of its strategic holding, Vivasure Medical Limited, by Haemonetics Corporation, with $11 million expected in 2026.


Key Events · Financing and Capital Events · OBIO

  • Significant Cash Proceeds

    Orchestra BioMed expects to receive up to $21 million in cash proceeds from the acquisition of Vivasure Medical Limited by Haemonetics Corporation.

  • Immediate Liquidity Boost

    Approximately $11 million of the total proceeds are anticipated to be received during 2026, comprising $5 million upfront and a $6 million first milestone payment.

  • Validation of Strategic Holding

    Vivasure Medical Limited was a strategic holding for Orchestra BioMed, demonstrating the success of its investment and partnership model.

  • Non-Dilutive Capital

    The proceeds represent a significant non-dilutive capital inflow, enhancing the company's balance sheet without issuing new shares.


Analysis · OBIO · Industrial Applications And Services

Orchestra BioMed Holdings, Inc. is set to receive a substantial cash infusion from the acquisition of Vivasure Medical Limited, a strategic holding. This non-dilutive capital strengthens the company's financial position and provides additional resources for its operations and pipeline development. The upfront and near-term milestone payments offer immediate liquidity, while future earnouts provide potential for further upside. This event validates Orchestra BioMed's strategy of investing in and supporting biomedical innovations through risk-reward sharing partnerships.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OBIO was trading at $4.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $273.3M. The 52-week trading range was $2.20 to $6.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OBIO - Latest Insights

OBIO
Nov 12, 2026, 4:27 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $6.23
Real-time Price: $7.38 info
Change: +$1.15 (+18%) info
Market Cap: $584.778M info
OBIO
Nov 10, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.73
Real-time Price: $7.38 info
Change: +$1.65 (+29%) info
Market Cap: $584.778M info
OBIO
Nov 06, 2026, 5:11 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.68
Real-time Price: $7.38 info
Change: +$1.70 (+30%) info
Market Cap: $584.778M info
OBIO
Nov 05, 2026, 10:43 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $7.38 info
Change: +$2.38 (+48%) info
Market Cap: $584.778M info
OBIO
Nov 05, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $5.56
Real-time Price: $7.38 info
Change: +$1.82 (+33%) info
Market Cap: $584.778M info